Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.

Pellicori, Pierpaolo; Ferreira, João Pedro; Mariottoni, Beatrice; Brunner-La Rocca, Hans-Peter; Ahmed, Fozia Z; Verdonschot, Job; Collier, Tim; Cuthbert, Joe J; Petutschnigg, Johannes; Mujaj, Blerim; +10 more... Girerd, Nicolas; González, Arantxa; Clark, Andrew L; Cosmi, Franco; Staessen, Jan A; Heymans, Stephane; Latini, Roberto; Rossignol, Patrick; Zannad, Faiez; Cleland, John GF; (2020) Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European journal of heart failure. ISSN 1388-9842 DOI: https://doi.org/10.1002/ejhf.1716

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1002/ejhf.1716

Abstract

Item Type Article
Faculty and Department Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID 31950604
Elements ID 144139

Share

Download

Embargo Date: 16 January 2021

Restricted to: Repository staff only

Request a copy

Filename: HOMAGE RCT Design paper accepted.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

[img]

Downloads

View details

Metrics & Citations


Google Scholar